@article{oai:kanazawa-u.repo.nii.ac.jp:00014356,
 author = {Shimadoi, Shigeru and Takami, Akiyoshi and Kondo, Yukio and Okumura, Hirokazu and Nakao, Shinji},
 issue = {9},
 journal = {Cancer Science},
 month = {Sep},
 note = {Recent studies suggest that monocytes are the dominant effectors by which rituximab induces cell death in B-cell lymphoma. Because macrophage colony-stimulating factor (M-CSF) can enhance the cytotoxicity of monocytes, the authors examined whether this growth factor can enhance their ability to kill lymphoma cells in vitro. Monocytes derived from a healthy volunteer were cultured for 48 h in the presence or absence of M-CSF. Monocytes stimul ated with M-CSF were significantly more cytotoxic to Daudi B-cell lymphomas than unstimulated monocytes. Flow cytometry revealed that M-CSF increased monocyte expression of Fcγ receptors III and I by 1.6- and 1.5-fold, whereas the expression of Fcγ receptor II remained unchanged. These results suggest that pretreatment with M-CSF can improve the therapeutic efficacy of rituximab against intractable CD20+ lymphoma. © 2007 Japanese Cancer Association., 医薬保健研究域医学系},
 pages = {1368--1372},
 title = {Macrophage colony-stimulating factor enhances rituximab-dependent cellular cytotoxicity by monocytes},
 volume = {98},
 year = {2007}
}